NASDAQ:ANIK - Anika Therapeutics Stock Price, News & Analysis

$55.91
-0.85 (-1.50 %)
(As of 08/25/2019 01:14 PM ET)
Today's Range
$54.4653
Now: $55.91
$57.32
50-Day Range
$39.57
MA: $49.62
$57.50
52-Week Range
$29.01
Now: $55.91
$58.93
Volume111,144 shs
Average Volume257,091 shs
Market Capitalization$770.44 million
P/E Ratio27.69
Dividend YieldN/A
Beta1.08
Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$105.56 million
Cash Flow$2.2636 per share
Book Value$18.21 per share

Profitability

Net Income$18.72 million

Miscellaneous

Employees133
Market Cap$770.44 million
Next Earnings Date10/23/2019 (Estimated)
OptionableOptionable

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.


Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) issued its quarterly earnings data on Wednesday, July, 24th. The biotechnology company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.42 by $0.25. The biotechnology company earned $30.42 million during the quarter, compared to analyst estimates of $27.41 million. Anika Therapeutics had a return on equity of 11.27% and a net margin of 26.87%. The business's revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.68 EPS. View Anika Therapeutics' Earnings History.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, October 23rd 2019. View Earnings Estimates for Anika Therapeutics.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics updated its FY 2019 earnings guidance on Wednesday, July, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $106.61055-109.7772 million, compared to the consensus revenue estimate of $101.89 million.

What price target have analysts set for ANIK?

4 brokerages have issued 1 year target prices for Anika Therapeutics' shares. Their predictions range from $35.00 to $54.00. On average, they anticipate Anika Therapeutics' stock price to reach $46.00 in the next twelve months. This suggests that the stock has a possible downside of 17.7%. View Analyst Price Targets for Anika Therapeutics.

What is the consensus analysts' recommendation for Anika Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics.

What are Wall Street analysts saying about Anika Therapeutics stock?

Here are some recent quotes from research analysts about Anika Therapeutics stock:
  • 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (7/26/2019)
  • 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on ANIK shares and are increasing our price target to $49 (from $45 previously). We arrive at our price target by attaching a 15x multiple to our 2020 adjusted EBITDA estimate. We assume $140 million in net cash 12 months from now." (7/25/2019)

Has Anika Therapeutics been receiving favorable news coverage?

Headlines about ANIK stock have trended positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Anika Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Anika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), Mylan (MYL), Alibaba Group (BABA), Broadcom (AVGO), Clovis Oncology (CLVS), Exelixis (EXEL) and GW Pharmaceuticals PLC- (GWPH).

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:
  • Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
  • Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
  • Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
  • Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)
  • Mr. Alexei Goraltchouk, VP of Operations

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.67%), Kayne Anderson Rudnick Investment Management LLC (11.81%), Vanguard Group Inc. (6.65%), Renaissance Technologies LLC (3.22%), D. E. Shaw & Co. Inc. (3.00%) and BTIM Corp. (2.61%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

Which institutional investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Capital Management Corp VA, Invesco Ltd., Marshall Wace LLP, Pinebridge Investments L.P., South Dakota Investment Council, JPMorgan Chase & Co. and Bank of America Corp DE. Company insiders that have sold Anika Therapeutics company stock in the last year include Jeffery S Thompson, Joseph L Bower and Raymond J Land. View Insider Buying and Selling for Anika Therapeutics.

Which institutional investors are buying Anika Therapeutics stock?

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, BTIM Corp., D. E. Shaw & Co. Inc., Natixis Advisors L.P., Renaissance Technologies LLC, Morgan Stanley, 361 Capital LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Anika Therapeutics.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $55.91.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $770.44 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.View Additional Information About Anika Therapeutics.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is http://www.anikatherapeutics.com/.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]


MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel